Message from the Chief

Madhav Dhodapkar, MBBS

Madhav Dhodapkar, MBBS

Welcome to the Section of Hematology. Our section has a long and rich tradition of excellence in clinical care, research and training in hematology. We offer comprehensive clinical care and research programs in both non-malignant and malignant hematologic diseases as well as hematopoietic stem cell transplantation.

The section’s nationally and internationally renowned faculty are leaders in their areas of research and clinical expertise, and are committed to advancing the science and practice of hematology by understanding the molecular basis of disease, and translating basic discoveries to the clinic. The section also has a strong tradition of training and several of the alumna of this program are current leaders in hematology across the nation.

Over the past few years, the section has been in the midst of a tremendous growth phase, with substantial increase in both clinical and research programs. Opening of the Smilow Cancer Center in October 2009 heralded a major increase in the capacity for cancer care and research at Yale, including for hematologic malignancies. Our hematopoietic stem cell transplant (SCT) program has consistently reported excellent outcomes for patients undergoing both autologous as well as allogeneic SCT. The section also has integrated clinical and research programs including both physicians and physician-scientists with expertise in leukemia, lymphoma and plasma cell disorders including myeloma. All of these programs have grown considerably in recent years and provide patients with access to newer therapies including clinical trials. Collaborations with colleagues in the Department of Laboratory Medicine provide comprehensive consultative programs in coagulation medicine. The section is also home to an emerging comprehensive multi-disciplinary program to facilitate care of patients with sickle cell disease.

Establishment of a new Cancer Biology Institute on Yale’s west campus has further enhanced basic cancer research at Yale, including for hematologic malignancies. The section’s faculty also have active collaborations and joint appointments with several of the basic science departments at Yale, including immunobiology, genetics, and the Yale Stem Cell Institute. Several of our faculty have active laboratory programs in blood diseases. A major emphasis is on translating basic discoveries in the laboratory towards new approaches to improve outcome in both malignant as well as non-malignant blood-related diseases. I urge you to visit the pages of the individual faculty and research programs to learn more about the diversity and expertise of the outstanding clinical and research programs in the section.